Optic neuritis is the presenting feature of MS in 15 to 20 percent of patients and occurs in 50 percent of patients with MS at some time during the course of their illness.
The Elon Musk-founded neurotechnology company has begun to recruit participants for clinical trials. Canadian residents with limited or no ability to use both hands due to ALS or cervical spinal cord injury are eligible to apply